These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22702493)

  • 1. Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients.
    Seredina TA; Goreva OB; Talaban VO; Grishanova AY; Lyakhovich VV
    BMC Med Genet; 2012 Jun; 13():45. PubMed ID: 22702493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
    Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
    Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of xenobiotic metabolism enzyme gene polymorphism in the formation of chemotherapy resistance in patients with chronic lymphoproliferative diseases.
    Gorbachenko EA; Goreva OB; Domnikova NP; Grishanova AY
    Bull Exp Biol Med; 2013 Sep; 155(5):676-9. PubMed ID: 24288737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy.
    Tulsyan S; Agarwal G; Lal P; Mittal B
    Clin Chim Acta; 2014 Jul; 434():21-8. PubMed ID: 24768782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
    Bosch TM; Meijerman I; Beijnen JH; Schellens JH
    Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.
    DeMichele A; Aplenc R; Botbyl J; Colligan T; Wray L; Klein-Cabral M; Foulkes A; Gimotty P; Glick J; Weber B; Stadtmauer E; Rebbeck TR
    J Clin Oncol; 2005 Aug; 23(24):5552-9. PubMed ID: 16110016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.
    van Schaik RH
    Invest New Drugs; 2005 Dec; 23(6):513-22. PubMed ID: 16267627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients.
    Jernström H; Bågeman E; Rose C; Jönsson PE; Ingvar C
    Br J Cancer; 2009 Dec; 101(11):1817-23. PubMed ID: 19935798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis.
    Modugno F; Knoll C; Kanbour-Shakir A; Romkes M
    Breast Cancer Res Treat; 2003 Dec; 82(3):191-7. PubMed ID: 14703066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach.
    Tulsyan S; Chaturvedi P; Singh AK; Agarwal G; Lal P; Agrawal S; Mittal RD; Mittal B
    Gene; 2014 Jun; 543(1):69-75. PubMed ID: 24704000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.
    Gor PP; Su HI; Gray RJ; Gimotty PA; Horn M; Aplenc R; Vaughan WP; Tallman MS; Rebbeck TR; DeMichele A
    Breast Cancer Res; 2010; 12(3):R26. PubMed ID: 20459744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of CYP2C19*2 (rs4244285) and CYP17 (rs743572) SNPs on Adriamycin and Paclitaxel based Chemotherapy Outcomes in Breast Cancer Patients.
    Gudur RA; Bhosale SJ; Gudur AK; Kale SR; More AL; Datkhile KD
    Asian Pac J Cancer Prev; 2024 Jun; 25(6):1977-1986. PubMed ID: 38918659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents.
    van Schaik RH
    Ther Drug Monit; 2004 Apr; 26(2):236-40. PubMed ID: 15228172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase.
    Velazquez MNR; Parween S; Udhane SS; Pandey AV
    Biochem Biophys Res Commun; 2019 Jul; 515(1):133-138. PubMed ID: 31128914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression.
    Temesvári M; Kóbori L; Paulik J; Sárváry E; Belic A; Monostory K
    J Pharmacol Exp Ther; 2012 Apr; 341(1):294-305. PubMed ID: 22262920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population.
    Hilli J; Rane A; Lundgren S; Bertilsson L; Laine K
    Fundam Clin Pharmacol; 2007 Aug; 21(4):379-86. PubMed ID: 17635176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
    Bray J; Sludden J; Griffin MJ; Cole M; Verrill M; Jamieson D; Boddy AV
    Br J Cancer; 2010 Mar; 102(6):1003-9. PubMed ID: 20179710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements.
    Saraeva RB; Paskaleva ID; Doncheva E; Eap CB; Ganev VS
    J Clin Pharm Ther; 2007 Dec; 32(6):641-9. PubMed ID: 18021343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population.
    Ganoci L; Božina T; Mirošević Skvrce N; Lovrić M; Mas P; Božina N
    Drug Metab Pers Ther; 2017 Mar; 32(1):11-21. PubMed ID: 28272018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P450 in Pharmacogenetics: An Update.
    Tornio A; Backman JT
    Adv Pharmacol; 2018; 83():3-32. PubMed ID: 29801580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.